Stempeutics Research Pvt. Ltd. signed an option licence agreement with Japan’s Medinet Co. Ltd., a listed regenerative medicine company. The deal enables Medinet to develop and commercialise Stempeucel, Stempeutics’ stem cell-based therapy for chronic limb-threatening ischemia (CLTI), in Japan.
Bringing Indian Innovation to a Tough Regulatory Market
BN Manohar, CEO of Stempeutics, said the partnership marks a crucial step in taking Indian-origin cell therapy global. Medinet will conduct a pivotal clinical study in Japan, while Stempeutics will provide regulatory support and manufacture the product in India. Once certain regulatory milestones are achieved, Medinet can exercise exclusive rights to commercialise Stempeucel in Japan.
Stempeutics, part of the Manipal Education & Medical Group, has Cipla holding a 34% stake. Cipla markets Stempeucel in India, where regulators have approved it for CLTI, and doctors have administered it to more than 600 patients.
Medinet’s Vision for Addressing Unmet Needs
Kanenao Kubushiro, President and Representative Director of Medinet, said, “We are happy to partner with Stempeutics since its product Stempeucel has already been approved in India and patented in Japan. The clinical data from India will support our pivotal study approval in Japan. CLTI is a serious and painful condition that impacts many patients, and we are eager to introduce this therapy soon.”
Pioneering India-Japan Collaboration in Cell Therapy
As reported by thehindubusinessline.com, the partnership represents a major step in India-Japan collaboration within regenerative medicine. By combining Stempeutics’ proven technology with Medinet’s regulatory and clinical expertise, the alliance sets the stage for delivering advanced cell-based therapies to a global patient base — reaffirming India’s growing leadership in the next generation of biotherapeutics.
